Board of Directors

Board of Directors

John Pedersen


John Pedersen joined DYSIS Medical as Chairman of the Board in December 2019.  Prior to joining the Board of Directors, John was CEO at Augmenix, Inc., which in was acquired by Boston Scientific Corp. in late 2018.  Previous to Augmenix, he was a Senior Healthcare Advisor for two Healthcare Private Equity Funds – The Gores Group and The Pritzker Group. Prior to this, John was President of the Urology and Women’s Health Division at Boston Scientific. During his 15 years at Boston Scientific, he also served as President of the Peripheral Interventions and the Neurovascular Divisions. Prior to Boston Scientific, he was a Senior Engagement Manager at McKinsey & Co.  John earned an MBA from The Harvard Graduate School of Business Administration and an AB degree from Princeton University.

Darin Hammers

Chief Executive Officer

Darin Hammers has served as Chief Executive Officer of the Company since September 2018. Mr. Hammers’ experience includes over 25 years of increasing leadership roles in Gynecology and Urology. Prior to joining DYSIS, he served as the President and CEO of Cogentix Medical which was acquired by Laborie in April of 2018.  He joined Cogentix’s predecessor company Uroplasty as Vice President of Global Sales in January 2013 and was promoted to Chief Operating Officer prior to being named interim President and CEO in May 2016, and President and CEO in July 2016. Prior to joining Uroplasty, Mr. Hammers was Vice President of Sales for Bard Medical Division of C.R. Bard based in Covington, GA, focused on Urology care products. Prior to that, Mr. Hammers spent more than 12 years with Boston Scientific in various sales leadership positions in the Urology/Gynecology areas.

Casper Breum

Casper Breum was previously CEO of ilochip A/S, a venture backed company focused on development of diagnostic biochips. Before this he held different positions at H.Lundbeck A/S most recently in corporate business development and strategy where he gained broad international experience. He was also a member of the Board of Directors of the Lundbeck Foundation and Lundbeckfond Invest as an employee representative. Prior to his work at H.Lundbeck, Casper worked for Novo Nordisk A/S and Niels Clauson-Kaas A/S. Casper has an MSc in organic chemistry and an MBA.